COCRYSTAL PHARMA NEW O.N. Net Assets
COCRYSTAL PHARMA NEW O.N. net assets. Based on the latest financial reports, COCRYSTAL PHARMA NEW O.N. (8CC) has net assets worth €6.33 Million EUR (≈ $7.40 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€9.71 Million ≈ $11.35 Million USD) and total liabilities (€3.38 Million ≈ $3.95 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore COCRYSTAL PHARMA NEW O.N. (8CC) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €6.33 Million |
| % of Total Assets | 65.19% |
| Annual Growth Rate | -46.55% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 12.66 |
Net Assets of COCRYSTAL PHARMA NEW O.N. (2021–2025)
Net assets of COCRYSTAL PHARMA NEW O.N. from 2021 to 2025. This chart illustrates how COCRYSTAL PHARMA NEW O.N.'s net assets have evolved over time, based on quarterly financial data. See COCRYSTAL PHARMA NEW O.N. balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for COCRYSTAL PHARMA NEW O.N. (2021–2025)
The table below shows the annual net assets of COCRYSTAL PHARMA NEW O.N. from 2021 to 2025. For live market cap and overall valuation, see COCRYSTAL PHARMA NEW O.N. market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €6.33 Million ≈ $7.40 Million |
-33.52% |
| 2024-12-31 | €9.52 Million ≈ $11.13 Million |
-63.91% |
| 2023-12-31 | €26.38 Million ≈ $30.85 Million |
-33.32% |
| 2022-12-31 | €39.57 Million ≈ $46.26 Million |
-48.98% |
| 2021-12-31 | €77.55 Million ≈ $90.66 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to COCRYSTAL PHARMA NEW O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8315600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
COCRYSTAL PHARMA NEW O.N. Net Assets Breakdown (December 2025)
COCRYSTAL PHARMA NEW O.N. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €348.58 Million | 5505.92% |
| Total Equity | €6.33 Million | 100.00% |
COCRYSTAL PHARMA NEW O.N. Competitors by Market Cap
The table below lists competitors of COCRYSTAL PHARMA NEW O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Malpac Holdings Bhd
KLSE:4936
|
$13.56 Million |
|
OPG POWER VENTURES (OPB.SG)
STU:OPB
|
$13.57 Million |
|
Thanasiri Group Public Company Limited
BK:THANA
|
$13.57 Million |
|
Stallion Uranium Corp.
V:STUD
|
$13.57 Million |
|
Biotechnology Assets S.A.
MC:BST
|
$13.52 Million |
|
Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
|
$13.52 Million |
|
Arcoma AB
ST:ARCOMA
|
$13.52 Million |
|
Bravada Gold Corporation
V:BVA
|
$13.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in COCRYSTAL PHARMA NEW O.N.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,523,000 to 6,331,000, a change of -3,192,000 (-33.5%).
- Net loss of 8,831,000 reduced equity.
- New share issuances of 5,369,000 increased equity.
- Other factors increased equity by 270,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-8.83 Million | -139.49% |
| Share Issuances | €5.37 Million | +84.8% |
| Other Changes | €270.00K | +4.26% |
| Total Change | €- | -33.52% |
Book Value vs Market Value Analysis
This analysis compares COCRYSTAL PHARMA NEW O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.83x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.09x to 1.83x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €9.55 | €0.84 | x |
| 2022-12-31 | €4.86 | €0.84 | x |
| 2023-12-31 | €2.59 | €0.84 | x |
| 2024-12-31 | €0.94 | €0.84 | x |
| 2025-12-31 | €0.46 | €0.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently COCRYSTAL PHARMA NEW O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -139.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.53x
- Recent ROE (-139.49%) is below the historical average (-101.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -18.29% | 0.00% | 0.00x | 1.02x | €-21.94 Million |
| 2022 | -98.16% | 0.00% | 0.00x | 1.03x | €-42.79 Million |
| 2023 | -68.16% | 0.00% | 0.00x | 1.18x | €-20.62 Million |
| 2024 | -183.81% | 0.00% | 0.00x | 1.41x | €-18.46 Million |
| 2025 | -139.49% | 0.00% | 0.00x | 1.53x | €-9.46 Million |
Industry Comparison
This section compares COCRYSTAL PHARMA NEW O.N.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| COCRYSTAL PHARMA NEW O.N. (8CC) | €6.33 Million | -18.29% | 0.53x | $13.54 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About COCRYSTAL PHARMA NEW O.N.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hep… Read more